Given the recent development of selective ROCK2 inhibitors, such as KD02539, we next investigated whether the observed effects of ROCK2 on MYC protein stability in ABC-DLBCL could be pharmacologically targeted. Here, ROCK2 is linked to diffuse large B-cell lymphoma.